Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
May 2016
-
Media ReleaseNovartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of NovartisPaul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis Paul Hudson and Bruno Strigini appointed to the…
-
Media ReleaseNovartis Foundation and partners launch innovative hypertension program in VietnamHo Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening and treatment shifts to the…
-
Media ReleaseMajor study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbationsFLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients Ultibro…
April 2016
-
Media ReleaseNovartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumorsIf approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional…
-
Media ReleaseNovartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever SyndromesSubject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential…
-
Media ReleaseNovartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growthNet sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…
-
Media ReleaseNovartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complexEverolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1] Seizures are the most…
-
Media ReleaseSandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indicationSandoz' epoetin alfa product offering has already generated more than 400,000[1] patient years of experience worldwide EC approval expands Sandoz biosimilar offering to the healthcare community…
-
Media ReleaseNovartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITPEU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily…
-
Media ReleaseNew analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
March 2016
-
Media ReleaseNovartis publishes updated 2015 segment financials reflecting new division structureUpdated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY…
-
Media ReleaseNovartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeksNew data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks[1] Cosentyx delivered and sustained skin…
Pagination
- ‹ Previous page
- 1
- …
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- …
- 88
- › Next page